This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Dr. Parmis Mojarab, DO·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

Compounded GLP-1 safety: what the adverse-event data shows

Quick answer

Compounded GLP-1 drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before marketing. As of February 28, 2025 the FDA had logged more than 455 adverse-event reports for compounded semaglutide and more than 320 for compounded tirzepatide. The single most common failure is a dosing error — and it is a failure mode the brand devices do not have.

The reported harms

Reported harms — FDA adverse-event dataAs of February 28, 2025, the FDA had received more than 455 adverse-event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide. A recurring cause is dosing error: patients or clinicians measuring the wrong volume from a multi-dose vial, sometimes by a factor of ten. Brand auto-injectors and single-dose vials remove that failure mode; a compounded multi-dose vial reintroduces it.

Why dosing errors happen with compounded vials

A brand pen or single-dose vial delivers a fixed, pre-measured dose. A compounded multi-dose vial requires the patient (or a clinician) to draw the correct volume with a syringe. The FDA has documented cases of patients and clinicians miscalculating by as much as a factor of ten, some requiring hospitalisation.

This is the clearest concrete safety difference between the two products, and it has nothing to do with the molecule — it is the delivery format.

Semaglutide salts are not semaglutide

Semaglutide salts are not semaglutideSome compounded products use semaglutide salts — semaglutide sodium or semaglutide acetate. These are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has stated they are not approved for use in compounding. A program that will not state its exact salt form and concentration cannot be evaluated on safety.

What separates a legitimate programme

A verifiable pharmacy licence, a named prescriber, a disclosed salt form and concentration, and no 'research use only' language. A programme that will not tell you its exact formulation cannot be assessed on safety, and should be treated accordingly.

The comparison that actually matters now

The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of July 12, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.

For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.

Brand vs compounded — monthly cost, verified July 12, 2026

Brand figures are verified against manufacturer pricing pages. The compounded figure is the lowest advertised rate we have seen and is unverified. Note where the brand oral tablet sits.

Frequently asked questions

Are compounded GLP-1 drugs safe?

They are not FDA-verified for safety, effectiveness or quality. The FDA has received 455+ adverse-event reports for compounded semaglutide and 320+ for compounded tirzepatide, with dosing errors a recurring cause. Risk depends heavily on the pharmacy and the delivery format.

What is the biggest safety risk?

Dosing error from self-measured multi-dose vials. Brand pens and single-dose vials remove this failure mode entirely.

What are semaglutide salts?

Semaglutide sodium and semaglutide acetate are salt forms that are not the same active ingredient as the semaglutide base in Wegovy and Ozempic. The FDA has stated they are not appropriate for compounding.

Sources

U.S. Food and Drug Administration — labels and safety communications.
Peer-reviewed clinical trials cited above.
Our methodology and medical review policy.

Spotted an error? Submit a correction.